Researchers are excited about new treatments for hepatitis

March 1996

Researchers are excited about new treatments for hepatitis...especially the chronic, active forms of hepatitis B and C.

Antivirals are being tried...ribavirin for chronic hepatitis C and the new HIV drug, lamivudine (3TC), for chronic hepatitis B.

But no antivirals are approved for hepatitis...because their clinical benefit hasn't been shown. The ribavirin being studied for hepatitis is an ORAL form...not the aerosol version used for RSV.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote